Long-Term Follow-Up Confirms Sustained Benefits of Adjuvant Pembrolizumab in High-Risk Clear Cell Renal Cell Carcinoma

Adjuvant pembrolizumab查看药品详情 continues to deliver sustained clinical benefits for patients with clear cell renal cell carcinoma (搜索)搜索该疾病 (ccRCC (搜索)搜索该疾病) at increased risk of recurrence, according to comprehensive 5-year follow-up results from the pivotal phase 3 KEYNOTE-564 study. The long-term data, representing the longest follow-up for adjuvant immune checkpoint inhibitor therapy in this setting, demonstrate durable improvements in disease-free survival and overall survival compared to placebo.

Extended Follow-Up Reveals Durable Efficacy

At a median follow-up of 69.5 months, the median disease-free survival (DFS) was not reached with pembrolizumab查看药品详情 (n = 496) versus 68.3 months with placebo (n = 498), representing a 29% reduction in the risk of disease recurrence or death (HR, 0.71; 95% CI, 0.59-0.86). The estimated 6-year DFS rate was 58.5% with pembrolizumab compared to 48.7% with placebo, demonstrating sustained separation of survival curves that began early in the treatment course.

Overall survival benefits were similarly maintained, with median OS not reached in either arm but showing a 34% reduction in the risk of death with pembrolizumab查看药品详情 (HR, 0.66; 95% CI, 0.48-0.90). The estimated 6-year OS rates were 86.1% with pembrolizumab versus 79.4% with placebo.

"This is the first time that the results from the study have reached a median landmark analysis of 6 years. This is the longest data [we've seen] presented for adjuvant ICI therapy," said Naomi B. Haas, MD, professor of medicine at the Hospital of the University of Pennsylvania查看公司主页 and director of the Prostate and Kidney Cancer Program at the Abramson Cancer Center查看公司主页.

Consistent Benefits Across Patient Subgroups

Subgroup analyses revealed that DFS benefits were consistent across all prespecified categories, regardless of risk stratification or tumor characteristics. In patients with M0 intermediate-high risk disease, the HR for DFS was 0.75 (95% CI, 0.61-0.93), while those with M0 high risk showed an HR of 0.61 (95% CI, 0.35-1.08). Patients with M1 no evidence of disease (NED) demonstrated particularly strong benefit with an HR of 0.48 (95% CI, 0.25-0.92).

The presence of sarcomatoid features, historically associated with poor prognosis, did not diminish pembrolizumab查看药品详情's efficacy. Patients with sarcomatoid features achieved an HR for DFS of 0.56 (95% CI, 0.33-0.96), while those without sarcomatoid features had an HR of 0.75 (95% CI, 0.60-0.92).

Secondary Endpoints Support Primary Findings

Pembrolizumab查看药品详情 also demonstrated superior distant metastasis-free survival (DMFS), with median DMFS not reached compared to 80.7 months with placebo (HR, 0.73; 95% CI, 0.60-0.89). Time to recurrence similarly favored the immunotherapy, with median time not reached versus 80.9 months with placebo (HR, 0.69; 95% CI, 0.57-0.84).

Among patients who experienced disease recurrence, subsequent therapy patterns were comparable between treatment arms. In the pembrolizumab查看药品详情 group (n = 171), 64.3% received systemic therapy compared to 68.1% in the placebo group (n = 226). VEGF (搜索)搜索该靶点 or VEGFR (搜索)搜索该靶点 inhibitors were used in 59.1% of pembrolizumab patients versus 58.8% of placebo patients, while anti-PD(L)1 therapy (搜索)搜索该药品 was administered to 28.7% and 48.2%, respectively.

Real-World Evidence Confirms Clinical Trial Results

Complementing the KEYNOTE-564 findings, real-world data from the international ARON-1 study provide additional validation of pembrolizumab查看药品详情's effectiveness in routine clinical practice. The observational study enrolled 311 patients with ccRCC (搜索)搜索该疾病 at intermediate-high or high risk of recurrence across 40 hospitals in 12 countries.

At a median follow-up of 15.4 months, patients achieved a 2-year OS rate of 95% and a 2-year DFS rate of 69%. Disease recurrence occurred in 20% of patients, most commonly in the lungs (11%) and bones (5%). However, certain patient subgroups experienced worse DFS outcomes, including those 65 years of age or younger (HR 2.14; P = 0.005), patients with sarcomatoid dedifferentiation (HR 2.54; P = 0.007), and those with N1 disease (HR 5.42; P = 0.004).

Safety Profile Remains Manageable

Long-term safety data from KEYNOTE-564 confirmed a stable toxicity profile with no new serious adverse events emerging beyond three years of treatment. In the real-world ARON-1 study, serious adverse events led to treatment discontinuation in 19% of patients, with the most common events being hypertransaminasemia (4%), colitis (4%), and nephritis (3%).

Study Design and Regulatory Impact

The KEYNOTE-564 study was a randomized, double-blind, placebo-controlled phase 3 trial that enrolled patients with histologically confirmed ccRCC (搜索)搜索该疾病 at intermediate-high or high risk of recurrence, or M1 with NED following nephrectomy and/or metastasectomy. Patients received pembrolizumab查看药品详情 200 mg intravenously every 3 weeks for approximately one year or up to 17 cycles, or matching placebo.

The study's primary endpoint was investigator-assessed DFS, with secondary endpoints including OS and safety. The initial interim analysis demonstrated significant DFS improvement (HR, 0.68; 95% CI, 0.53-0.87; P = 0.0010), leading to FDA approval of adjuvant pembrolizumab查看药品详情 for this indication in November 2021.

These extended follow-up results reinforce pembrolizumab查看药品详情's role as a standard adjuvant treatment for patients with ccRCC (搜索)搜索该疾病 at increased risk of recurrence, providing healthcare providers with confidence in the therapy's long-term benefit-risk profile.